TP53 and neoplasm: After a median follow-up of 6.9 years and adjusting for PSA level, Gleason score, clinical stage, and change in tumor volume, men with abnormal p53 expression compared with normal were at increased risk of PSA failure (hazard ratio [HR]: 2.8; 95% confidence interval [CI]) [76].